<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792310</url>
  </required_header>
  <id_info>
    <org_study_id>MIN-001-1203</org_study_id>
    <secondary_id>EudraCT 2012-001527-13</secondary_id>
    <nct_id>NCT01792310</nct_id>
  </id_info>
  <brief_title>A Phase 1/2A Study of Minerval in Adult Patients With Advanced Solid Tumours</brief_title>
  <official_title>A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minerval®) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laminar Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Specialized Medical Services (SMS)-Oncology BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Institute for Cancer Research, Newcastle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vall d'Hebron Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Oncológico IMQ, Clínica IMQ Zorrotzaurre. Bilbao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onkologikoa, San Sebastián.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laminar Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2A, open label, non-randomized study in patients with advanced solid&#xD;
      tumours including malignant glioma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, non-randomized study in patients with advanced solid tumours including&#xD;
      malignant glioma. The study will be performed in two phases - a dose escalation phase&#xD;
      following a standard &quot;3+3&quot; design to establish dose-limiting toxicity (DLT) and a safe dose&#xD;
      of 2-OHOA followed by two expanded safety cohorts (approximately 10 of whom have malignant&#xD;
      glioma and approximately 10 of whom have other advanced solid tumours that are suitable for&#xD;
      biopsy) treated at the maximum tolerated dose (MTD). If the MTD is well tolerated in the&#xD;
      expanded safety cohorts, that dose becomes the recommended phase 2 dose (RP2D). During each&#xD;
      dose cohort, at least one week must elapse between the first and subsequent patients&#xD;
      receiving treatment with 2-OHOA. Patients may receive palliative localized radiotherapy, if&#xD;
      needed (however, this lesion cannot be a target lesion for evaluation of the treatment&#xD;
      response).&#xD;
&#xD;
      Safety, pharmacokinetics (PK), pharmacodynamics and efficacy will be evaluated during the&#xD;
      study at pre-defined timepoints&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>From the first dose of study drug until 30 days after the last dose of study drug</time_frame>
    <description>All adverse events will be recorded including clinically significant physical examinations and vital signs, laboratory safety tests and 12-lead electrocardiograms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of 2-OHOA in blood measured by LC-MS/MS</measure>
    <time_frame>21 days</time_frame>
    <description>Full profiles on Day 1 and Day 21 (dose escalation phase only), trough measurements on Day 8, 15 and 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of biomarkers in blood or tumour tissue</measure>
    <time_frame>First 22 days then every 9 cycles until any criterion for discontinuation is met (clinical or radiological progression of disease, clinically unacceptable toxicity, or another &quot;general&quot; discontinuation criterion)</time_frame>
    <description>Effect on glial fibrillary acidic protein in glioma patients and effect on sphingomyelin and dihydrofolate reductase in patients with other solid tumours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of micro RNA in blood</measure>
    <time_frame>First 22 days then every 9 cycles until any criterion for discontinuation is met (clinical or radiological progression of disease, clinically unacceptable toxicity, or another &quot;general&quot; discontinuation criterion)</time_frame>
    <description>Blood samples for future analysis of micro RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological disease progression</measure>
    <time_frame>Every 6 weeks until any criterion for discontinuation is met (clinical or radiological progression of disease, clinically unacceptable toxicity, or another &quot;general&quot; discontinuation criterion)</time_frame>
    <description>Measurement by CT or MRI scan. Changes scored according to Response Assessment in Neuro-oncology (RANO) criteria (for glioma patients) or Response evaluation criteria in solid tumours (RECIST v1.1) (for other solid tumour patients).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical disease progression</measure>
    <time_frame>until any criterion for discontinuation is met (clinical or radiological progression of disease, clinically unacceptable toxicity, or another &quot;general&quot; discontinuation criterion</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Glioma</condition>
  <condition>Other Solid Tumours</condition>
  <arm_group>
    <arm_group_label>Dose Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 7 dose cohorts of up to 6 patients have been performed in the dose escalation phase. The starting dose cohort received 250 mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 500 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 1g twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-OHOA Dose Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 2g twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-OHOA Dose Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-OHOA Dose Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-OHOA Dose Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 8g twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-OHOA Dose Expansion cohort. Glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with malignant glioma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-OHOA Dose Expansion cohort. Non-glioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with other advanced solid tumours that are suitable for biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-hydroxyoleic acid (2-OHOA/2OHOA)</intervention_name>
    <description>Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another &quot;general&quot; discontinuation criterion) is met.&#xD;
Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.&#xD;
In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of 2-OHOA may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment &quot;holidays&quot; of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances.</description>
    <arm_group_label>2-OHOA Dose Cohort 4</arm_group_label>
    <arm_group_label>2-OHOA Dose Cohort 5</arm_group_label>
    <arm_group_label>2-OHOA Dose Cohort 6</arm_group_label>
    <arm_group_label>2-OHOA Dose Cohort 7</arm_group_label>
    <arm_group_label>2-OHOA Dose Expansion cohort. Glioma</arm_group_label>
    <arm_group_label>2-OHOA Dose Expansion cohort. Non-glioma</arm_group_label>
    <arm_group_label>Dose Cohort 1</arm_group_label>
    <arm_group_label>Dose Cohort 2</arm_group_label>
    <arm_group_label>Dose Cohort 3</arm_group_label>
    <other_name>Minerval®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Males or females providing written, informed consent&#xD;
&#xD;
          -  Histologically- or cytologically-confirmed advanced solid malignancy that is&#xD;
             refractory to standard-of-care treatment, or for which there is no standard therapy.&#xD;
             If this is glioma:Grade III / Grade IV malignant glioma recurring or progressing after&#xD;
             first or second line standard-of-care treatment and true progressive disease,&#xD;
             confirmed according to the RANO criteria 4.&#xD;
&#xD;
          -  Life-expectancy of at least 12 weeks&#xD;
&#xD;
          -  Eastern cooperative oncology group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  Safety laboratory tests and ECGs within specified limits.&#xD;
&#xD;
          -  Using adequate contraception, where applicable&#xD;
&#xD;
          -  Presence of lesions suitable for biopsy (mandatory for non-glioma patients enrolled in&#xD;
             the expanded safety cohort and highly desirable for non-glioma patients enrolled in&#xD;
             the dose escalation phase)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Anti cancer therapy within 4 weeks (6 weeks for mitomycin and nitrosureas and 2 weeks&#xD;
             for palliative radiotherapy)&#xD;
&#xD;
          -  NCI Common terminology criteria for adverse events (CTCAE) &gt;Grade 1 toxicities from&#xD;
             prior chemotherapy or radiotherapy that could impact on safety outcome assessment&#xD;
&#xD;
          -  Recent &gt;Grade 1 intracranial or intratumoural haemorrhage either by CT or MRI scan.&#xD;
             Patients with resolving haemorrhage changes, punctuate haemorrhage or haemosiderin may&#xD;
             enter the study&#xD;
&#xD;
          -  Significant or uncontrolled cardiovascular disease, unstable angina or myocardial&#xD;
             infarction within the preceding 6 months&#xD;
&#xD;
          -  Known impairment of GI function that could alter the absorption of study drug&#xD;
&#xD;
          -  History of uncontrolled hyperlipidemia and/or the need for concurrent lipid lowering&#xD;
             therapy&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled other medical disease that could compromise&#xD;
             participation in the study&#xD;
&#xD;
          -  Taking warfarin, phenytoin or sulphonylureas (glibenclamide, glimepiride, glipizide,&#xD;
             glyburide or nateglanide)&#xD;
&#xD;
          -  Pregnant or breast feeding Other protocol specific criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Johann de Bono, MB ChB FRCP MSc PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Ruth Plummer, BMBCh, MRCP, Cert Me</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Institute for Cancer Research, Newcastle</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Jordi Rodon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d'Hebron Institute of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Juanita Lopez</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey, United Kingdom SM2 5NG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Ricardo Fernandez Rodriguez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Oncológico IMQ, Clínica IMQ Zorrotzaurre. Bilbao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Ander Urruticoechea Ribate</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onkologikoa, San Sebastián.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vall D'Hebron Institute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oncológico IMQ, Clínica IMQ Zorrotzaurre</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologikoa</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Cancer Trials Research Centre, The Northern Centre for Cancer Care, Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>Newcastle upon Tyne</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital Drug Development Unit</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM25PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>http://www.lipopharma.com/index.php/en/</url>
    <description>Lipopharma website</description>
  </link>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 24, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioma</keyword>
  <keyword>Solid Tumours</keyword>
  <keyword>Minerval</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

